<DOC>
	<DOCNO>NCT02638467</DOCNO>
	<brief_summary>Patients newly diagnose chronic phase chronic myeloid leukemia undergo treatment TK inhibitor ( TKI ) . A possible cause TK failure represent insufficient recovery normal Ph- hematopoiesis TKI treatment , consequent severe cytopenia limit TKI adequate administration . Although rare , event happen proportion 4-5 % CML patient . Our hypothesis circumvent peculiar condition provide normal hematopoiesis HLA-matched donor ( Human Leukocyte Antigen ) . The transplant procedure therefore intend providing sustain hematopoiesis allow early treatment adequate dosing TKI . The transplant procedure plan study build available evidence provide low incidence acute chronic GvHD ( Graft-versus-host disease ) . Therefore , bone marrow preferential source GvHD prophylaxis base Anti-thrombocyte globulin ( ATG ) Cyclosporine/Methotrexate use accord standard current experience field family unrelated donor . The pre-transplant TKI continue aplasia develop , order decrease tumor load much possible.The use TKIs shortly transplant carry risk inhibit newly transplant hematopoietic cell , Kit , important kinase normal bone marrow cell , frequently block Abl inhibitor . The use bosutinib post-transplant therapy justify lack Kit inhibition distinguishes bosutinib TKIs , could allow minimal inhibitory activity transplant normal bone marrow .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Failing TKIs Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>1 . Chronic Myeloid Leukaemia CML chronic phase ( CP ) 2 . Failure achieve least Major Cytogenetic Response ( MCyR ) minimum 18 month TKIs treatment 3 . Inability tolerate 3 month uninterrupted full dose TKIs therapy due hematological toxicity 4 . A minimum three treatment interruption due hematological toxicity Availability HLAidentical relate donor ( Matched Related Donor , MRD ) 5 . Availability unrelated donor ( Matched Unrelated Donor , MUD ) satisfy criterion 10/10 antigen match ( Human Leukocyte Antigen ) HLAA , B , C DRB1 , DQB1 high resolution typing , 9/10 permissive DP disparity accord Fleischhauer model ( Crocchiolo et al , Blood 2009 ) 6 . Target graft size ( bone marrow ) : 7. bone marrow : &gt; 3 x 106 CD34+ cells/kg BW recipient &gt; 3 x 108 nucleated cells/kg BW 8 . Karnofsky Index &gt; 80 % 9 . Age ≥18 ≤70 year 10 . Adequate contraception female patient childbearing potential 11 . Written inform consent 1 . Secondary malignancy 2 . A hematopoietic cell transplantationspecific comorbidity index ( Sorror et al Appendix C ) &gt; 4 3 . Known manifested malignant involvement Central Nervous System ( CNS ) 4 . Active infectious disease 5 . Active human immunodeficiency virus ( HIV ) , Hepatitis B virus ( HBV ) Hepatitis B virus ( HCV ) infection 6 . Impaired liver function ( Bilirubin &gt; upper normal limit ; Transaminases &gt; 3.0 x upper normal limit ) 7 . Impaired renal function ( Creatinineclearance &lt; 60 ml/min ; Serum Creatinine &gt; 1.5 x upper normal limit ) . 8 . Pleural effusion ascites &gt; 1.0 L 9 . Pregnancy lactation 10 . Known hypersensitivity Busilvex and/or fludarabine 11 Noncooperative behaviour noncompliance 12 Psychiatric disease condition might impair ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>